Resistin Contribution to Cardiovascular Risk in Chronic Kidney Disease Male Patients
Cells · 2023
DOI: 10.3390/cells12070999 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2023. Verfasst von Katarzyna Romejko und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Diseases, Nephrology and Dialysis, Military Institute of Medicine-National Research Institute, 04-141 Warsaw, Poland. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Military Institute of Medicine, Warsaw, Poland.
Abstract (Originalsprache)
Background
Resistin is a molecule that belongs to the Resistin-Like Molecules family (RELMs), the group of proteins taking part in inflammatory processes. Increased resistin concentrations are observed in cardiovascular complications. Resistin contributes to the onset of atherosclerosis and intensifies the atherosclerotic processes. The aim of this study was to investigate the relationship between resistin and cardiovascular (CV) risk in men with chronic kidney disease (CKD) not treated with dialysis. Materials and Methods: One hundred and forty-two men were included in the study: 99 men with eGFR lower than 60 mL/min/1.73 m2 and 43 men with eGFR ≥ 60 mL/min/1.73 m2. CV risk was assessed. Serum resistin, tumor necrosis factor-alpha (TNF-alpha) and plasminogen activator inhibitor-1 (PAI-1) were measured among other biochemical parameters.
Results
We observed that resistin concentrations were significantly higher in patients with CKD compared to individuals with eGFR ≥ 60 mL/min/1.73 m2 (p = 0.003). In CKD, after estimating the general linear model (GLM), we found that resistin is associated with CV risk (p = 0.026) and PAI-1 serum concentrations (0.012). The relationship of PAI-1 with resistin depends on the level of CV risk in CKD (p = 0.048).
Conclusions
Resistin concentrations rise with the increase of CV risk in CKD patients and thus resistin may contribute to the progression of cardiovascular risk in this group of patients. The relationship between resistin and CV risk is modified by PAI-1 concentrations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Diseases, Nephrology and Dialysis, Military Institute of Medicine-National Research Institute, 04-141 Warsaw, Poland.
- Department of Epidemiology and Biostatistics, Institute of Mother and Child, 01-211 Warsaw, Poland.
- Department of Internal Diseases and Endocrinology, Medical University of Warsaw, 02-097 Warsaw, Poland.
- Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
ORCID-Profile: Katarzyna Romejko, Aleksandra Rymarz
Förderung
- Military Institute of Medicine, Warsaw, Poland
Zitieren
APA
Romejko, K., Rymarz, A., Szamotulska, K., Bartoszewicz, Z., Rozmyslowicz, T., & Niemczyk, S. (2023). Resistin Contribution to Cardiovascular Risk in Chronic Kidney Disease Male Patients. Cells. https://doi.org/10.3390/cells12070999
Vancouver
Romejko K, Rymarz A, Szamotulska K, Bartoszewicz Z, Rozmyslowicz T, Niemczyk S. Resistin Contribution to Cardiovascular Risk in Chronic Kidney Disease Male Patients. Cells. 2023. doi:10.3390/cells12070999
BibTeX
@article{Romejko2023,
author = {Romejko, Katarzyna and Rymarz, Aleksandra and Szamotulska, Katarzyna and Bartoszewicz, Zbigniew and Rozmyslowicz, Tomasz and Niemczyk, Stanisław},
title = {Resistin Contribution to Cardiovascular Risk in Chronic Kidney Disease Male Patients},
journal = {Cells},
year = {2023},
doi = {10.3390/cells12070999}
}
EUVIMED